Compare Regeneron Pharmaceuticals Inc (REGN) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs 22nd Century Group Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while 22nd Century Group Inc trades at $2.12 (market cap $1.62M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 51500× 22nd Century Group Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| REGN | XXII | |
|---|---|---|
Market Cap | $83.43B | $1.62M |
Sector | Health | Technology |
52-Week High | $852.03 | $594.00 |
52-Week Low | $555.51 | $2.13 |
Enterprise Value | $78.14B | -$2.69M |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
XXII trades at $2.29, down 4.58% today, showing continued bearish momentum with negative technical signals. The company faces severe financial challenges with negative profit margins (-76.01% net income margin) and consecutive earnings misses. Despite analyst optimism (75% buy ratings), fundamental weakness persists with declining revenue and substantial losses. Recent corporate actions include a 20:1 reverse stock split completed June 2026 to maintain listing compliance.
The outlook remains challenging given persistent operational losses and negative cash flow from operations. Investment opportunity exists if the company can capitalize on its claimed $50B market opportunity and improve gross margins. Key risks include continued cash burn, competitive pressures in tobacco alternatives, and execution challenges in commercializing VLN products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
